Dong-A ST revealed on Monday that it presented findings from a clinical trial comparing its SGLT-2 inhibitor diabetes treatment, DA-2811 (brand name Dapapro), with Farxiga at the American Diabetes Association (ADA) Scientific Sessions.
At the poster presentation, Professor Hong Jun-hwa from the Department of Endocrinology at Daejeon Eulji University Hospital showcased clinical results on the Comparison of Metabolic, Hepatic, Renal, and Hemodynamic Effects of DA-2811 and Farxiga in Type 2 Diabetes Patients.
The study, a multicenter, randomized, double-blind, active-controlled, parallel-group trial, involved 225 type 2 diabetes patients who received either DA-2811 or Farxiga for 24 weeks to assess efficacy and safety. Researchers evaluated various clinical markers, including glycemic control, metabolism, liver and kidney function, blood pressure, and body weight.
Results demonstrated that DA-2811 was non-inferior to Farxiga in HbA1c (glycated hemoglobin) changes at 24 weeks. It also showed comparable outcomes to Farxiga in metabolic and hepatic indicators, such as increased the high-density lipoprotein (HDL) cholesterol, decreased triglycerides, and reduced liver enzyme and uric acid levels. Both systolic and diastolic blood pressure decreased similarly to Farxiga, with comparable reductions in weight and waist circumference.
A Dong-A ST spokesperson emphasized the significance of the trial, stating that this study highlights DA-2811’s clinical profile, which mirrors Farxiga’s not only in glycemic control but also across metabolic, hepatic, renal, cardiovascular, and weight-related parameters. They added that they’re committed to continuing our research to provide patients with enhanced treatment options.
In other news, Dong-A ST reported first-quarter 2026 revenues of 187.1 billion KRW (approximately 122.12 million USD), a 10.7% year-over-year increase. Operating profit for the same period surged 53.7% to 10.8 billion KRW (approximately 7.05 million USD).
The company’s growth was primarily driven by its ETC (prescription drug) division, which saw sales climb 22.8% year-over-year to 144 billion KRW (about 93.98 million USD).